Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30520309 | 0.80 | KDM4E (0.59) | LTA4HRAB9AKDM4EHTR2CALDH1A1 | |
| SCHEMBL19198136 | 0.80 | KMT2A (0.54) | LTA4HRAB9AKDM4EHTR2CGSK3B | |
| SCHEMBL3254598 | 0.80 | KDM4E (0.59) | LTA4HRAB9AKDM4EHTR2CALDH1A1 | |
| SCHEMBL563869 | 0.80 | HDAC3 (0.47) | KDM4EHDAC1ALDH1A1EGFRHDAC3 | |
| SCHEMBL31438448 | 0.80 | HDAC3 (0.47) | KDM4EHDAC1ALDH1A1EGFRHDAC3 | |
| SCHEMBL19198153 | 0.78 | ALDH1A1 (0.64) | LTA4HRAB9AKDM4EHTR2CGSK3B | |
| SCHEMBL19197793 | 0.78 | KDM4C (0.61) | LTA4HRAB9AKDM4EHTR2CGSK3B | |
| SCHEMBL25415696 | 0.76 | RAB9A (0.51) | LTA4HRAB9AKDM4EHTR2CGSK3B | |
| SCHEMBL30520324 | 0.76 | RAB9A (0.51) | LTA4HRAB9AKDM4EHTR2CGSK3B | |
| SCHEMBL13926774 | 0.75 | KDM4E (0.62) | LTA4HRAB9AKDM4EHTR2CGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11214542-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10807956-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10597365-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-10179769-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180044296-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-9725441-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-4450164-A | ANTIULCER AND ANTISECRETORY AGENTS | SCHERING CORPORATION (US) | 1984-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-11214542-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-20170298025-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-10179769-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-10807956-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-20180044296-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
| US-10597365-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | LTA4H 2790/4885RAB9A 3032/4885KDM4E 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.